减量FLAG方案治疗难治老年急性髓细胞白血病30例临床观察

FLAG regimen in the treatment of refractory reducing acute myeloid leukemia aged 30 cases

目的:探讨减量阿糖胞苷的FLAG方案治疗难治老年急性髓细胞白血病(AML)的疗效及不良反应。方法:本研究采用减量阿糖胞苷FLAG方案,氟达拉滨150mg,静脉滴注,30min滴完,第1～5天;阿糖胞苷150mg/m2,静脉滴注,第1～5天;G-CSF化疗前1d开始应用,直至化疗结束。治疗30例难治性老年急性髓细胞性白血病。结果:30例患者中,13例难治性老年急性髓细胞白血病达完全缓解(CR率为43.3%),6例达部分缓解(PR率为20.0%),总有效率为63.3%,无效7例,死亡4例。减量阿糖胞苷的FLAG方案的主要不良反应为骨髓抑制、消化道症状、轻度肝损害等。结论:减量阿糖胞苷的FLAG方案对难治老年急性髓细胞白血病治疗缓解率相对较高,不良反应可以接受。

Objective： To investigate the reduction of Ara-C in the FLAG regimen in the treatment of refractory acute myeloid leukemia（AML） in elderly efficacy and adverse reactions. Methods： In this study, FLAG cytarabine reduction programs, fludarabine 150 mg, intravenous infusion, 30 min after dropping the first 1 to 5 days; Ara-C 150 mg/m2, intravenous infusion, the first 1 to 5 days; G-CSF starting 1 d before the application of chemotherapy until the end of chemotherapy. 30 patients with refractory acute myeloid leukemia. Results： 30 patients, 13 patients with refractory acute myeloid leukemia achieved complete remission （CR rate was 43.3%）, 6 cases of partial remission （PR rate was 20.0%）, the total effective rate was 63.3%, invalid 7 cases, 4 deaths. Ara′s FLAG reduction program′s main adverse reactions were myelosuppression, gastrointestinal symptoms, mild liver damage and so on. Conclusion： The reduction of the FLAG program Ara-C in refractory acute myeloid leukemia relatively high response rate, adverse reactions can be accepted.